The blood–brain barrier (BBB) serves as a protective endothelial barrier that safeguards the central nervous system (CNS) from dangerous substances while maintaining its stable condition. The brain health function of this barrier creates a major challenge that prevents effective treatment delivery for neurological conditions. This review describes the molecular and physiological mechanisms that control BBB function while demonstrating the difficulties faced by CNS drug delivery through emerging methods that scientists use to improve their drug delivery systems. The main transport pathways consist of four methods, which include paracellular diffusion, transcellular lipophilic passage, receptor-mediated transcytosis, and carrier-mediated transport. The presence of efflux pumps, including P-glycoprotein, restricts the ability of many drugs to enter the CNS, which results in insufficient medication levels. The development of drug design methods together with nanoparticle carriers and receptor-targeting ligands and transient BBB disruption techniques creates new opportunities to solve these obstacles. The research community uses computational models and imaging methods to forecast CNS drug distribution patterns and establish optimal treatment plans. The progress achieved so far faces a major obstacle because different medical conditions, age groups, and genetic variations cause different levels of BBB integrity. The review analyzes experimental and clinical research to deliver an all-inclusive assessment of BBB permeability and CNS drug delivery. The research combines mechanistic insights with emerging technologies to establish a basis for future development of therapeutic solutions and precise medical treatment methods in neurology. Understanding BBB dynamics and penetration strategies is essential for the effective treatment of CNS disorders, which include neurodegenerative diseases, brain tumors, and psychiatric conditions. The research shows that targeted approaches that investigate BBB physiology and pathophysiology can improve CNS drug delivery methods while reducing systemic toxicity.

The blood–brain barrier (BBB) functions as a physiological structure that brain microvascular endothelial cells, pericytes, and astrocytic endfeet create to control molecular passage between systemic blood flow and the central nervous system (CNS) [1–3]. The barrier establishes brain protection against pathogens and toxins while maintaining stable neuronal functions in the brain [2,4]. The boundary restricts blood flow, which creates a major obstacle that hinders doctors from using medicines to treat neurological diseases like Alzheimer’s disease and Parkinson’s disease, multiple sclerosis, and gliomas [5–7]. The delivery of drugs to the central nervous system depends on various factors, which include molecular weight and lipophilicity, and the presence of transport proteins and P-glycoprotein, which functions as an efflux mechanism [8–10]. Researchers who develop methods to boost CNS absorption need to create effective solutions that protect the barrier functions. The field now benefits from advanced methods that enhance drug delivery through nanotechnology and receptor-mediated transport and temporary blood-brain barrier disruption methods [11–13]. The review presents an extensive description of blood-brain barrier physiology, together with drug penetration mechanisms and existing difficulties and new treatment methods. The research combines molecular and pharmacological, and translational knowledge to create new methods which will enable safe and effective delivery of drugs to the central nervous system [14,15].

Literature Review

The BBB consists of tight junctions between endothelial cells that prevent paracellular diffusion of most hydrophilic molecules [16]. The BBB uses multiple transportation methods to control substance movement between its boundaries.

Paracellular diffusion: Limited to small hydrophilic molecules [16,17].

Transcellular lipophilic pathway: Endothelial membranes allow lipophilic molecules to pass through them [18].

Carrier-mediated transport: Glucose, amino acids, and all-important nutrients use specific transport proteins for their movement [19].

Receptor-mediated transcytosis: Cells take in insulin, transferrin, and other ligands, which they then use to move across the endothelial barrier [20,21].

The CNS experiences reduced drug bioavailability because efflux transporters such as P-glycoprotein and breast cancer resistance protein remove xenobiotics from the brain [8,22]. Preclinical studies show that nanoparticle systems and peptide shuttles and focused ultrasound-induced BBB opening can enhance CNS drug delivery [11,23]. Clinical translation faces many challenges because of individual differences in patients and the various ways blood-brain barrier function changes during disease, and the dangers that systemic toxicity presents [12,24,25].

Research Methodology

The review combines findings from experimental studies, clinical trials, and computational modeling methods. Researchers conducted database searches in PubMed, Scopus, and Web of Science using keywords “blood–brain barrier” and “CNS drug delivery,” and “nanoparticles” and “drug penetration” [1,5]. In studies, researchers included both in vitro BBB models and in vivo studies that examined drug permeability and delivery enhancement methods [14]. The researchers extracted statistical analyses from primary studies to evaluate efficacy and pharmacokinetic results, which were accessible [11,23].

The literature analysis shows that small lipophilic drugs achieve better BBB penetration than large biologics, which need carrier-mediated transport or nanoparticle encapsulation to cross the barrier [11,16]. Nanoparticle delivery systems enhance bioavailability to the central nervous system by 200 to 1000 percent in preclinical testing [11,23]. The combination of focused ultrasound and chemical BBB modulators enables temporary permeability increases that assist in delivering therapeutic substances throughout the body without causing permanent damage to the barrier [12,25]. Efflux pump inhibitors enable some drugs to accumulate in the central nervous system, but they cause toxic effects throughout the body [8,22].

                                                                               Table 1: Mechanisms of Drug Transport Across the Blood–Brain Barrier.

                                                                                           Table 2: Strategies to Enhance CNS Drug Penetration.

                                                                                   Figure 1: Concept: Blood–Brain Barrier Structure and Transport Mechanisms.

Source: Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiology of Disease. 2010;37(1):13–25.

                                                                                                       Figure 2: Concept: CNS Drug Delivery Enhancement Strategies.

Source: Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. Journal of Controlled Release. 2016; 235:34–47.

The process by which drugs access the central nervous system depends on the molecular properties of the drugs and the presence of particular transport proteins and changes to the blood-brain barrier that occur during medical conditions [5,7,10]. The development of nanotechnology and molecular targeting techniques shows great potential, but researchers must assess their safety profile and drug absorption characteristics [11,23]. The use of personalized treatment methods that consider variations in blood-brain barrier function and patient age and genetic makeup will enhance the effectiveness of central nervous system medication distribution [3,15]. Drug distribution and dose calculations become possible through the combination of imaging techniques with computational simulation methods [14,19].

Researchers must study blood-brain barrier function and the processes that control how drugs enter the central nervous system to create effective treatments for brain disorders [1,5,7]. New research methods, which use nanoparticle-based drug carriers and targeted receptor delivery systems and temporary blood-brain barrier breakdown, show potential to solve current problems [11–13]. Researchers should study the development of delivery systems that ensure safety and precision and individual patient needs because these systems will improve treatment outcomes while decreasing harmful effects on the body [3,15,24].

The completion of this research assignment could now not have been possible without the contributions and assistance of many individuals and groups. We’re. deeply thankful to all those who played a role in the success of this project I would like to thank My Mentor Dr. Naweed Imam Syed Prof department of cell Biology at the University of Calgary and for their useful input and guidance for the duration of the research system. Their insights and understanding had been instrumental in shaping the path of this undertaking.

Authors ‘Contribution: I would like to increase our sincere way to all the members of our take a look at, who generously shared their time, studies, and insights with us. Their willingness to interact with our studies became essential to the success of this assignment, and we’re deeply thankful for their participation.

Conflict of Interest: The authors declare no conflict of interest.

Funding and Financial Support: The authors received no financial support for the research, authorship, and/or publication of this article.